CA2562329C - Therapeutic antimicrobial compositions and methods - Google Patents
Therapeutic antimicrobial compositions and methods Download PDFInfo
- Publication number
- CA2562329C CA2562329C CA002562329A CA2562329A CA2562329C CA 2562329 C CA2562329 C CA 2562329C CA 002562329 A CA002562329 A CA 002562329A CA 2562329 A CA2562329 A CA 2562329A CA 2562329 C CA2562329 C CA 2562329C
- Authority
- CA
- Canada
- Prior art keywords
- acid
- use according
- bacteria
- composition
- antimicrobial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/30—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests characterised by the surfactants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/16—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
- A61L2/18—Liquid substances or solutions comprising solids or dissolved gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Abstract
Therapeutic antimicrobial compositions and methods for providing enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, coronovirus, respiratory syricytial virus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, therapeutic antimicrobial compositions comprising an organic acid or organic acid mixture and a short-chain anionic surfactant having at least one of a large head group; a branched alkyl chain and an unsaturated alkyl chain, and therapeutic methods of use thereof.
Description
THERAPEUTIC ANTIMICROBIAL COMPOSITIONS AND METHODS
FIELD OF THE INVENTION
The present invention relates to therapeutic antimicrobial coinpositions and methods that provide enhanced inunediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, the present invention relates to antimicrobial compositions comprising an organic acid or organic acid mixture, a specific, short-chain anionic surfactant having at least one of the following: a large, hydrophilic head group;
an unsaturated structure; and/or a branched structure, and therapeutic methods of using said compositions.
BACKGROUND OF THE INVENTION
Human and mammalian health is certainly impacted by the spread of microbial entities at home, school, work and in the environment generally. Indeed, viruses and bacteria continue to cause a variety of sicknesses and ailments, prompting high absenteeism in schools and places of employment. In the wake of widespread food poisoning and the like, the public has become even further concerned with sanitization, both of person and property. Consequently, those of skill in the art have focused their research endeavors on the identification and deployinent of suitable antimicrobial compositions, and specifically those that provide immediate and residual kill of microbes, with or without the use of water.
A comprehension of the vast benefits achieved via practice of the present invention requires an understanding of the various microbes against which the present compositions are effective. Bacteria found on human skin may be divided into two groups, namely, resident and transient bacteria. Resident bacteria are Gram-positive bacteria that establish as permanent microcolonies on the surface and outermost layers of the skin. Such bacteria play a fundamental role in preventing the colonization of other, more harmful bacteria and fungi. Transient bacteria are bacteria that are not part of the normal resident of the flora of the skin. Rather, transient bacteria are deposited when airborne contaminated material lands on the skin or when contaminated material is brought into physical contact with such bacteria. Transient bacteria are typically divided into two subgroups: Gram-positive and Gram-negative. Gram-positive bacteria include pathogens such as Staphylococcus aureus, Streptococcus pyogenes and Clostridiuni botulinun2. Gram-negative bacteria include pathogens such as Salnzonella, Escherichia coli, Klebsiella, Haemophilus, Pseudoinonas aeuginosa, Proteus and Shigella dysenteriae. Gram-negative bacteria are generally distinguished from Gram-positive bacteria via the existence of an additional protective cell membrane in the former, which often results in Gram-negative bacteria being less susceptible to conventional, topical antibacterial actives.
There exist several contemporary compositions and metliods for reducing and/or eliminating the formation of bacteria and/or viruses. For example, it is well known that the washing of hard surfaces, food (e.g. fruit or vegetables) and skin, especially the hands, with antimicrobial or non-medicated soap, is effective against viruses and bacteria.
Actually, removal of the viruses and bacteria is due to the surfactancy of the soap and the mechanical action of the wash procedure, rather than the function of an antimicrobial agent. Thus, it is recommended that people wash frequently to reduce the spread of viruses and bacteria. However, many conventional products and methods of sanitization, including washing, fail to address the dilemma of sanitization "on the go", that is to say, when a consuiner is removed from the benefit of running water. Those skilled in the art have attempted to resolve this dilemma via the incorporation of antimicrobial agents into disinfecting lotions, cleansing wipes and the like. Such articles reduce the need for water during or following the application of the subject composition.
Other conventional antimicrobial cleansing products include deodorant soaps, hard surface cleaners, and surgical disinfectants. These traditional, rinse-off antimicrobial products have been formulated to provide bacteria removal during washing.
A few such products, including antimicrobial soaps, have also been shown to provide a residual effectiveness against Gram-positive bacteria, but provide limited residual effectiveness against Gram-negative bacteria. By "residual effectiveness", it is meant that the subject antimicrobial controls microbial growth on a substrate by either preventing growth of microbes or engaging in continuous kill of microbes for some period of time following the washing and/or rinsing process. To address the dilemma of limited residual efficacy against Gram-negative bacteria, those skilled in the art have sought to incorporate high levels of alcohol and/or harsh surfactants into contemporary antimicrobial products, which have been shown to cause dryness and irritation to skin tissues.
Thus, there remains a substantial need to identify and deploy antimicrobial compositions that may be used by consumers "on the go"; provide immediate and residual kill of microbes with or without washing; and prevent dryness and irritation to skin following application. Despite providing a quasi solution to the dilemma of water availability, those skilled in the art have yet to identify antimicrobial compositions that address the problems associated with dryness and irritation to skin. In fact, attempts to resolve this dilemma have generally resulted in the adoption of aqueous-based antimicrobial formulas incorporating high levels of zwitterionic surfactants that are too weak to provide significant iinmediate or residual benefits. Others have attempted to address the dilemma of dryness or irritation to skin by incorporating cationic surfactants into antimicrobial compositions, which have been associated with adverse impacts on the environment and human health. Yet others still have attempted to resolve this dilenuna via the incorporation of long-chain anionic surfactants into antimicrobial coinpositions, which are intended to prevent skin tissue penetration. Nevertheless, such surfactants are often associated with poor phase stability in product, incompatibility with commercial antimicrobial agents, and low residual kill performance. Indeed, the identification of a balance between the factors of antimicrobial performance, skin mildness and water availability continues to be a key concern to those of skill in the antimicrobial art.
SUMMARY OF THE INVENTION
The present invention addresses and resolves all of the problems associated with the employment of conventional antimicrobial compositions and/or products.
Indeed, it has been surprisingly discovered that a composition incorporating an organic acid or organic acid mixture, a specific short-chain anionic surfactant having at least one of a large, hydrophilic head group; an unsaturated structure; and/or a branched structure;
constitutes a viable advancement and alternative in the realm of antimicrobial formulations. The antimicrobial compositions of the present invention are adapted for direct application to human skin, without causing dryness or irritation.
Moreover, the antimicrobial compositions of the present invention are designed for use with or without water, and provide immediate and residual effectiveness in either instance against a variety of viruses and bacteria, including rotavirus, rhinovirus, respiratory syricytial virus (RSV), coronavirus, Gram-positive and Gram-negative bacteria.
The specific, anionic surfactant of the present invention presents a particularly novel aspect of the present compositions. Those of skill in the art have generally relied upon the incorporation of longer chain (i.e. C12 to C16) anionic surfactants into antimicrobial compositions. Conventional surfactants, comparable to the acyl components found in the phospholipid matrix of the cell membrane of bacteria and virus, are thought to possess optimum antimicrobial activity with reduced skin tissue penetration. However, conventional anionic surfactants have been associated with low solubility under acidic conditions, poor compatibility with cationic antimicrobial agents, slow dissolution kinetics and limited residual antimicrobial performance.
Against the conventional wisdom in the art, the short chain anionic surfactants of the present invention comprise at least one of the following characteristics:
a large, hydrophilic head group; an unsaturated structure; and/or a branched structure.
Indeed, the surfactants of the present invention have traditionally been regarded as unsuitable for incorporation into an antimicrobial composition, based on the belief that such surfactants possess relatively low surface activity. Contrary to the traditional wisdom, it has been surprisingly discovered that the surfactants of the present invention deliver enhanced antimicrobial efficacy against rotavirus, rhinovirus, respiratory syricytial virus (RSV), coronavirus, Gram-negative bacteria and Gram-positive bacteria. More importantly, the large head group, unsaturated structure and/or branched structure of the present surfactants reduces or limits their tendency to penetrate skin tissue, while maximizing the immediate and residual effectiveness of the antimicrobial compositions in which they are incorporated. Further, the anionic surfactants of the present invention exhibit stability in an aqueous product at a low pH, are compatible with cationic antimicrobial agents and convey strong residual antimicrobial activity when the substrate on which they are applied is later inoculated with virus or bacteria.
Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof are described in commonly-assigned U.S. patent publication nos. US 2003/0235550 Al to Pan et al., December 25, 2003, US 2004/0001797 Al to Saud et al., January 1, 2004 and in published PCT
application WO 2004/000016 A2 to Pan et al., December 31, 2003.
These antimicrobial compositions comprise an organic acid or organic acid mixture, a specific short-chain anionic surfactant with branching or a large head group, and, optionally, a calcium ion scavenger and/or anti-foam agents.
In accordance with a first aspect of the present invention, therapeutic antimicrobial compositions and methods are disclosed. In one aspect, the present antimicrobial compositions comprise an organic acid or organic acid mixture, a specific, short-chain anionic surfactant mixture are disclosed. Suitable anionic surfactants for use in the context of the present invention comprise a chain length of from about C4 to C12 and at least one of the following characteristics: a large, hydrophilic head group; an unsaturated structure; and/or a branched structure. In yet another aspect, the antimicrobial compositions disclosed herein optionally further comprise a calcium ion scavenger and/or an anti-foam agent. The therapeutic methods and compositions of the present invention are adapted to provide immediate and residual Itill of numerous bacteria and viruses, with or without the use of water and without causing dryness or irritation to skin.
In accordance with another aspect of the present invention, there is provided a method of treating or provenfng a m=icarobial caused infection in a patient in need thereof, said method characterized by comprising the step of administering an efÃeotive amount of antimicrobial composition comprising: a. from 0.2% to 70% of an organic acid; and b. from 0.1 % to 40% of an anionic surfactant mixture having (i) a Iinear alkyl ohain length of from C4 to C12 and a total head group size of at least 4 Angstroms; and/or (n) a bxanehed alkyl chain length of from C4 to C12; and/or (iii) a branched alkyl chain length of from C4 to C12 and a total head group size of at least 4 Angstroms;
wherein said eomposition is characterized by a pH of from 2.0 to 4.5.
In accordance with another aspect of the present invention, there is provided a method of disinfecting devices characterized by comprising treating a device with an effective amount of an antimicrobial composition comprising: a. from 0.2%
to 70% of an organic acid; and b. from 0.1% to 40 /fl of an anionic surfactant mixture having i. a linear alkyl chain length of from C4 to C12 and a total head group size of at least 4 Angstroms; and/or ii. a branched alkyl chain length of from C4 to C12; and/or iii. a branched alkyl chain length of from C4 to Ci2 and a total head group size of at least 4 Angstroms; wherein said composition is eharacterized by a pH of from 2.0 to 4.5.
5a In accordance with another aspect of the present invention, there is provided a method of preventing infections originating in medical devices in a patient in need thereof characterized by comprising disinfecting the devices with an effective amount of an antimicrobial composition comprising: a. from 0.2% to 70% of an organic acid; and b.
from 0.1% to 40% of an anionic surfactant mixture having i. a linear alkyl chain length of from C4 to CIZ and a total head group size of at least 4 Angstroms; and/or ii.
abranched alkyl chain length of from C4 to C12; and/or iii. a branched alkyl chain length of from C4 to C12 and a total head group size of at least 4 Angstroms; wherein said composition is characterized by a pH of froan 2.0 to 4.5.
These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified. All temperatures are in degrees Celsius (0 C) unless otherwise specified.
DETAILED DESCRIPTION Op T'HE INVENTION
Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof are described in commonly-assigned U.S. patent publication nos. US 2003/0235550 Al to Pan et al., December 25, 2003, US 2004/0001797 Al to Saud et al., January 1, 2004 and in published PCT
application WO 2004/000016 A2 to Pan et al., December 31, 2003.
These compositions were stated to have effica.cy against gram negative and gram positive bacteria and also against viruses. We believe that certain formulations of these short chain, big head surfactant based antimicrobial compositions will be effective against a wide variety of pathenogenic agricultural organisms including but not limited to citrus canker.
These antimicrobial compositions comprise an organic acid or organic acid mixture, a specific short-chain anionic surfactant with branching or a large head group, and, optionally, a calcium ion scavenger and/or anti-foam agents. For therapeutic use the formulations require in addition to the surfactant, an organic acid acid and a nonionic agent. Preferred is to use C8-AGS as the surfactant, pyrrolidone carboxylic acid as the organic acid and ethylhexyl glycerol ether (EHOP) as the non-ionic agent. One of skill in the art will recognize that other agents as disclosed in U.S. patent publication nos. US
2003/0235550 Al to Pan et al., December 25, 2003, US 2004/0001797 Al to Saud et al., January 1, 2004 or published PCT application WO 2004/000016 A2 to Pan et al., December 31, 2003 may be substituted. Preferred are compositions having greater than about 0.50% C8AGS with most preferred compositions containing at least 1.25%
and a pyrrolidone carboxylic acid content of greater than or equal to 2.0%.
One of skill in the art will readily recognize that other active ingredients can be included to provide different properties or to improve the effectiveness of the present compositions against specific organisms. When adding other actives, the concentration of surfactants, acids and/or non-ionic agents would also be modified to provide the degree of activity desired. For example, Parachlorometaxylenol (PCMX), a known antimicrobial may be added to provide another broad spectrum antimicrobial. For example when adding PCMX, it is possible to reduce the amount of C8AGS below 1%
concentration by weight.
Five formulations of antimicrobial compositions were created having the active agents set forth in Table 1. Water makes up the balance of the formulation.
These formulations were made in accordance with U.S. patent publication nos. US
2003/0235550 Al to Pan et al., December 25, 2003, US 2004/0001797 Al to Saud et al., January 1, 2004 and in published PCT application WO 2004/000016 A2 to Pan et al., December 31, 2003.
Table 1.
Formula Active Component (WR M H KS KSM
C8-AGS 0.50 1.25 2.00 0.60 1.00 Coco Sulfofatty Acid 0.40 Gluconic Acid 2.00 P o lutamic Acid (PCA) 2.00 15.00 3.50 3.00 Succinic Acid 1.50 2.00 Ethylhexyl Glyceryl Ether EHOP 0.55 1.00 0.50 0.50 Parachlorometaxylenol (PCMX) 0.35 0.50 Potassium Sorbate 0.10 Formulation The composition of the present invention may be formulated for use in any manner lrnown to one of skill in the art. Formulations for topical, mucosal and aerosol delivery of drugs are taught in Modern Pharmaceutics by Gilbert S. Banker (Editor), Christopher T. Rhodes (Editor) Marcel Dekker; 4th edition (June 15, 2002) ISBN:
0824706749. Reference is also made to the International Journal of Pharmaceutical Compounding which can be accessed at www.ijpc.com. These sources teach and describe the basics of pharmaceutical compounding. One of skill in the art will know how to take the active ingredients of the present invention and formulate them for delivery. Such formulations may take the form. of lotions, ointments, gels, creams, drops washes, pastes, suppositories, lozenges, mouthwashes, gargles, douches, foams, surface coatings, liposomes, microspheres and transdermal patches.
One of skill in the art will appreciate that the activity of the present compositions can be affected through the selection of excipients to provide varying degree of skin penetration or to control release. Activity of the present formulations can be increased by occlusion of the skin after application with a suitable bandage or wrap. One of skill in the art will also recognize that persistent action can be increased by use of controlled release technologies which delay release of active over time.
The formulations contemplated herein can also be coated or otherwise incorporated into medical devices such as wipes, sponges, bandages, surgical drapes, hospital gowns, surgical gowns. Formulations can be developed that are suitable for disinfecting medical devices. Such formulations could be in the form of a liquid which could be used for spraying onto surfaces, soaking of devices, pumping through devices or incorporated into wipes for decontaminating a surface.
Testinll The formulations described above were tested for Minimum Bactericidal Dilution and Residual efficacy against C. Albicans, E. Coli, S. marcesens, Metlaicillin Resistant Staphylococcus aureus, and E. faecalis, Minimum Bactericidal Dilution.
Various formulations as set out in Table 2 below were tested for Minimum Bactericidal Dilution. Organisms to be tested were grown on slants and transferred to an agar plate by streaking to form a lawn. Colonies are scraped off the agar plates using a sterile innoculating loop and suspended in phosphate buffered solution (PBS) and diluted to 5 x 106 CFU/ml.
Table 2 MINIMUM BACTERICIDAL DILUTION
HTR Test C. faecalis E. coli P. S. S. aureus S. aureus albicans aeruginosa marcescens (MRSA) # Article 10231 51299 ~~E) 11229 15442 14756 6538 33591 0.1%
EHOP, 1 1.25% Inhibition 1:8 1:8 1:16 1:2 Undiluted Undiluted AGS, 8.5% PCA, 1 % EHOP, 2 A0.5 GS, Inhib'tion 1:2 1:16 1:8 1:4 Inhib tion Undiluted 2% PCA
0.1%
3 EHOP, 2% No 1:4 1:16 1:16 1:4 1:2 1:2 AGS, Inhibition 15% PCA
MINIMUM BACTERICIDAL DILUTION
C. E. P. S. S.aureus HTR Test faecalis E. coli S. aureus albicans aeruginosa marcescens (MRSA) # Article 10231 (VRE) 11229 15442 14756 6538 33591 0.1%
EHOP, 4 0.5% Inhibition Undiluted Undiluted 1:2 1:8 Undiluted 1:4 AGS, 15%
PCA
0.1%
EHOP, 2% No 1:4 1:2 1:8 1:8 1:2 1:8 AGS, Inhibition 2% PCA
0.55% 1:1024 EHOP, 1:4 6 1.25% hihiliirion 1:32 1:4 1:8 Undiluted 1:16 AGS, 1:4 15% PCA
0.1%
EHOP, 7 0.5% Inhibition Undiluted 1:8 1:8 Undiluted Inhibition Inhibition AGS, 2% PCA
1% EHOP, 8 2% AGS, Undiluted 1:32 1:32 1:64 1:64 1:16 1:2 15% PCA
1% EHOP, No 9 2% AGS, Inhibition 1:16 1:16 1:8 1:8 1:16 1:16 2% PCA
0.55%
EHOP, 2% Undiluted 1:16 1:32 1:4 1:2 1:4 1:8 AGS, 8.5% PCA
1% EHOP, 11 1.25% Undiluted Undiluted 1:2 1:4 1:4 1:4 1:8 AGS, 8.5% PCA
0.55% 1:16 EHOP, 1:4 12 1.25% Undiluted 1:2 1:8 1:2 1:4 1:8 AGS, 1:2 8.5% PCA
0.55%
EHOP, 13 1.25% Inhibition 1:16 1:8 1:4 1:4 1:4 1:4 AGS, 2%
PCA
0.55%
EHOP, 14 0.5% Inhibition 1:2 Undiluted 1:8 1:4 Undiluted Undiluted AGS, 8.5% PCA
1 % EHOP, 0.5% 15 AGS, Inhibition Undiluted Undiluted 1:4 1:16 Undiluted Undiluted 15% PCA
0.55% 1:32 EHOP, 1:4 16 1.25% Inhibition 1:8 1:16 1:32 Undiluted 1:2 AGS, Undiluted 8.5% PCA
0.55% 1:2048 EHOP, 1:4 17 1.25% Inhibition 1:32 1:8 1:32 1:8 Undiluted AGS, 1:8 8.5% PCA
0.55% 1:256 1:32 EHOP, 1:2 1:4 18 1.25% Inhibition 1:16 1:8 1:4 1:8 AGS, 1:2 1:4 8.5% PCA
0.55% 1:4 1:256 EHOP, 1:2 1:4 19 1.25% Inhibition 1:8 1:2 Undiluted 1:2 AGS, 1:2 1:4 8.5% PCA
0.55% 1:2048 EHOP, 1:16 1.25% Inhibition 1:16 1:32 1:2 Undiluted 1:2 AGS, 1:4 8.5% PCA
21 ChloraPrep 1:4 1:4 1:64 1:2 1:2 1:32 1:8 In Vitro Time Kill Candida Albicans was cultured under appropriate conditions. (current USP
procedures for culturing organisms is appropriate.) Incubation period varies (typically 120 hours at 25 C +/- 1 C) to a density of between 1.0E+06 - 1.0E+07 CFUs/mL.
Actual CFUs/mL of starting cultures were determined by serially diluting and plating an aliquot (typically plate 10-6, 10-5, 10"4 , 10-3, 10-2 dilutions). A 50 l aliquot of the yeast culture was pipetted into 5.OmL of the antimicrobial solution(s) in a sterile scintillation vial (organisms: solution ratio = 1:100) and mixed thoroughly by vortexing. Test inoculum level was - 1.0E+04-1.0E+05 CFUs/mL. At the predetermined time point(s), 1 min, 5 min, and 10 min, a 0.5mL aliquot of the inoculated antimicrobial solution is pipetted into 4.5mL of Dey/Engley (D/E) neutralizing broth (ratio = 1:10) and mixed by vortexing. An aliquot of the neutralized sample including yeast was plated onto a Sabouaud Dextrose Agar (SDA) plate using standard pour plate techniques. The SDA plates were incubated at 25 C+/- 1 C for 5 days (-120 hours) and CFU's are counted. CFUs/mL for organism cultures are calculated and compared to CFUs/mL for antimicrobial solutions to determine the log reductions.
Residual Skin Testing Residual skin testing was perfonned by evenly coating the surface of a skin patch with 20 1 of the active solution. Skin samples were allowed to evaporate for 1 minute, 15 minutes , 60 minutes, 120 minutes, 240 minutes,360 minutes, 480 minutes, and 14 hours with the lid off the Petri plate. At the appropriate time point, skin sainples were inoculated with 10 1 of a 1:10 dilution of the 18-hour microbial suspension (-1.0E+08 CFUs/mL), evenly covering the entire area and the sample recovered and allowed to sit 5 minutes. At this time the skin was extracted using sterile forceps and placed in a steril centrifuge tube.
Containing lOml of a sampling solution and vortexed for 30 seconds. An aliquot of the extracted sample containing any microbials from the skin was plated onto a trypticase soy agar plate using a spiral plater (typically 50 1 in exponential mode).
The agar plates were incubated at 37 C overnight (-18 hours) and CFUs are counted.CFUs/mL established by Baseline Count are calculated and compared to CFUs/inL for antimicrobial/bacterial solutions to determine the log reductions.
The Baseline Count was achieved by evenly spreading 10 1 of the diluted bacterial suspension on a square of the Skin and processed in accordance with the above procedure, except no active solution was added.
Test results Anti-Fungal/Yeast Activity Formulas R, M, H, KS and KSM were tested against Candida albicans and compared for activity with Chloraprep. The antifungal properties of these formulations were previously untested and unknown. In vitro time kill testing was performed as described above. The result of the testing are set forth in Table 3.
Table 3 In vitro time-kill of C. albicans 10231 Minutes of contact time (log reduction from log 5.0 titer) Formula sample 1 5 10 ChloraPrep (70% alcohol + 2% CHG) 4.8 4.8 4.8 KSM 4.8 4.8 4.8 M 1.3 4.8 4.8 RID 0.3 0.9 1.0 Residual Skin efficacy testing against C. albicans was performed as set forth above. The data are set forth in Table 4 below.
Table 4 Candida albicans (C. albicans 10231) Residual Efficacy Chlora- RID M H KS KSM
Log Reduction prep 1 min 3.6 0.8 2.3 3.4 3.6 3.6 15 min 2.2 1.1 2.7 3.9 3.6 3.6 60 min 2.5 0.9 2.9 3.9 3.6 3.6 120 min 1.8 2.1 3.2 3.9 3.6 3.6 240 min 1.1 0.2 2.7 3.9 3.6 3.6 The above data show that medically acceptable strengths of RID kill candida.
Faster kill, but not more residual activity can be obtained by adding known broad spectrum antimicrobial (PCMX).
E.Coli Formulas R, M, H, KS and KSM were tested against E. coli and compared with Chloraprep. Residual Skin efficacy testing against E.Coli was performed as set forth above. The data are set forth in Table 5 below.
Table 5 E. coli (E. coli 11229) Residual efficacy testing.
Chlora- RID M H KS KSM
Log Reduction prep 1 min 4.6 0.6 4.6 4.6 4.6 4.6 15 min 4.5 2.7 4.6 4.6, 3.7 4.5 60 min 4.1 4.5 4.6 4.6 4.6 4.6 120 min 3.3 3.7 4.6 4.2 4.6 4.6 240 min 3.9 4.0 4.6 4.1 4.6 4.6 Serratia marcesens (S. marcesens 14756) Formulas R, M, H, KS and KSM were tested against S. marcesens and compared with Chloraprep. Residual Skin efficacy testing against S. marcesens was performed as set forth above. The data are set forth in Table 6 below.
Table 6 S. marcesens 14756 Residual Efficacy Results Chlora- RID M H KS KSM
Log Reduction prep 1 min 1.8 0.1 3.6 6.0 5:1 5.1 15 min 0.7 0.1 3.6 6.0 5:1 5.1 60 min 2.0 0.9 2.0 6.0 4.5 5A
120 min 1.1 0.0 3.7 ' 6.0 5.1 5.1 240 min 1.0 0.2 2.8 6.0 5.1 5.1 Methicillin Resistant Staplzylococcus aureus (MRSA) Formulas R, M, H, KS and KSM were tested against MRSA and compared with Chloraprep. Residual Skin efficacy testing against MRSA was performed as set forth above. The data are set forth in Table 7 below.
Table 7 MRSA (S. aureus 33591) Residual Efficacy Results Chlora- R M H KS KSM
Log Reduction prep 1 min 5.5 1.3 0.9 4.9 5.1 5.1 15 min 1.4 0.2 0.6 3.9 5.0 4.9 60 min 2.7 0.1 0.6 2.9 5.8 4.9 120 min 3.9 0.3 1.3 4.0 4.8 4.5 240 min 3.7 0.4 1.7 4.6 5.0 4.8 Vancomycin Resistant Enterococci (VRE) Formulas R, M, H, KS and KSM were tested against E. faecalis and compared with Chloraprep. Residual Skin efficacy testing against E. faecalis was performed as set forth above. The data are set forth in Table 8 below.
Table 8VRE (E. faecalis 51299) Residual Efficacy Results Chlora- RID GMP / GMP / GMP / GMP /
Log Reduction prep M H KS KSM
1 min 4.3 0.5 4.7 4.7 4.8 4.8 15 min 1.1 1.3 4.5 4.7 4.8 4.4 60 min 1.5 2.0 4.7 4.7 4.8 4.8 120 min 1.7 2.8 4.7 4.7 4.6 4.8 240 min 3.2 0.6 4.7 4:7 4.8 4.8 Theraueutic examples Example 1 Acne Acne is a common disease affecting millions of Americans every year. The condition is characterized by lesions or pimples caused by infection with P.
acnes and/or P. granulosum bacteria. Common treatment is with topical retinoids, steroids, antibiotics, and topical counterirritants such as sulfur, benzoyl peroxide and/or alcohol and/or use of systemic antibiotics.
Acne could be treated and its spread prevented by topical administration of the formulations disclosed herein in a bar, pledget, lotion, gel, or cream.
Example 2 Atopic dermatits Atopic dermatits is a condition affecting 3-10% of the US. It most commonly affects young children and is characterized by scaly patches, small vescicles, excoriations, crusting, impetiginization caused by the presence of S. aureus in the horny layer of epidermis. Current treatment is with emollients, topical corticosteroids and/or topical or oral antihistamines. Severe cases may also be treated with UV-B phototherapy, psoralen + UVA, oral corticosteroids.
Antimicrobial compositions of the type disclosed herein have been shown to be useful in killing S. aureus bacteria. Atopic dermatits could be treated and its spread prevented through formulations of the present invention for topical administration in a soap, pledget, lotion, gel, or cream.
Example 3 Blepharitis Blepharitis causes lifelong chronic inflammation of eyelids is caused by Staphylococcus or yeast colonization on eyelid margins. Transmission is possible by touch. Current treatment includes use of warm compresses and lid scrubs. See, Harrison's Principals of Internal Medicine, 15th Edition.
Antimicrobial compositions of the type disclosed herein have been shown to be useful in killing S. aureus bacteria. Blepharitis could be treated and its spread prevented through formulations of the present invention for topical administration in ointments, drops, or other fomulations suitable for ocular administration.
Example 4 Diaper Rash/Dermatitis Diaper rash is caused by irritation from contact with urine and stool that leads to redness and breakdown of skin. Frequently accompanying common diaper rash is diaper dermatitis. Diaper dermatitis is most frequently caused by strains of the fungus Candida.
Secondary bacterial infections of staphylococcus and enterobacter are also possible.
Current treatments include zinc oxide cream and topical antifungal agents. It is believe that 20% of infants within first 2 years Only 10% of cases are reported. See Cecil Textbook of Medicine 22nd Edition 2004.
Treatment and/or prevention of the primary candida infection should be possible by use of the present forinulations in by application. Antimicrobial compositions of the type disclosed herein have been shown to be useful in killing candida, S.
aureus and enterobacter bacteria. Diaper rash and dermatitis could be treated and its spread prevented through formulations of the present invention for topical administration in a bar, pledget, lotion, gel, ointment or cream.
Example 5 Fungal skin infections A variety of skin infections are cause by fungal infection Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, demratophytes, yeasts and molds. Athlete's foot (tinea pedis) and nail fungus being among the more common.
Athletes foot is commonly treated with antifungal creams, sprays and powders, oral medications. Nail fungus and toenail fungus in particular are more difficult to treat due to the protective nail. Common OTC nail creams and ointments are relatively ineffective.
Oral antifungals such as itraconazole offer good efficacy but are expensive.
See Cecil Textbook of Medicine 22nd Edition 2004.
Fungal skin infections could be treated and its spread prevented through formulations of the present invention for topical administration in a bar, pledget, lotion, gel, ointment or cream.
Example 6 Impetigo Impetigo is the most common bacterial skin infection in children. This disease is characterized by various skin lesions, including bulla, vesicles and blisters caused by S.
aureus and/or Streptococcus. Impetigo contagiosa is the most common form, first appearing as blisters or red sores. Eventually, the blisters rupture and ooze a fluid that forms a cntst over the affected area. The sores may tend to itch, but generally do not cause pain although there may be swollen lymph nodes in the affected area.
Impetigo contagiosa is highly contagious and is readily spread to other parts of the body through touching or scratching the sores. It is also readily spread to others through personal contact and by sharing items with an infected person.
Impetigo contagiosa is readily treated through improved hygiene and topical antiobiotic ointments and/or oral antibiotics. In most cases, healing begins within three days of treatment. Though it is seldom serious, this infection can sometimes lead to complications, such as scarring, if left untreated. See Cecil Textbook of Medicine 22nd Edition 2004 and MayoClinic.com.
We believe that formulations of the present invention will treat and prevent impetigo by killing and stopping the txansfer of S. aureus and other bacteria.
Impetigo could be treated and its spread prevented through formulations of the present invention for topical administration in a bar, pledget, lotion, gel, ointment or cream.
Example 7 Thrush Oropharyngeal candidiasis (OPC) or thrush is a candida fungal infection of the mouth, throat and/or tongue. It is common in newborns, infants, and older adults, but can occur at any age. Thrush due to T-cell dysfunction is the most common opportunistic infection in HIV affecting 80-90% of all patients with advanced stages of HIV
infection.
Thrush is commonly treated with nonprescription and prescription antifungals and in HIV
infected patients through the concommitant use of oral azoles, and possibly intrvenous amphotericin in severe refractory cases. See Cecil Textbook of Medicine 22nd Edition 2004.
Thrush can be difficult to treat in infants due to the many places that candida species can hide. Reinfection may occur from toys, pacifiers, mother's breast, etc.
Because of the fast rate at which yeast multiply, Current therapies includ treatment with nystatin 4-8 or more times per day. The residual action of the present compositions should reduce frequency of application and improve rate of recovery by reducing ability of candida to hide and spread. Preferential application is topical application to mother's breasts, infant pacifiers and to swab affected areas of the mouth. Adults may also be treated in the same manner as well as with mouthwashes and gargles.
Example 8 Trachoma Trachoma is chronic conjuctival inflammation cause by C. trachomatis. It is conunon in developing world countries and is the cause of at least 4 million cases of blindness and 5 million cases of low vision. Current treatrnent is through surgury of the eyelid and topical antibiotics. See Cecil Textbook of Medicine 22nd Edition 2004.
Formulations of the present invention can be applied as drops or ointment to the eyes to treat and/or prevent spread of trachoma.
Example 9 Warts Warts are hard growths on skin cause by the Human papillomavirus. The primary treatment means is topical treatmentwith salicylic acid. See Cecil Textbook of Medicine 22nd Edition 2004.
Warts could be treated with the antiviral compositions of the present application through any topical formulation and/or use of treated bandages.
Example 10 Avian Flu/Influenza Avian flu is a highly infections and frequently fatal virus caused by Influenza A..
Its fatality rate is 33% vs. 10% for SARS. Treatment consists of destroying infected birds and decontaminating tools and clothing that may have come in contact with the virus using bleach solutions. See the World Health Organization Avian Influenza Fact Sheet 2004 available at http://www.who.int/mediacentre/factsheets/avan influenza/en/.
Formulations of the present invention could be administered to affected livestock via sprays to treat and prevent the spread of outbreaks. The present invention can also be used for decontamination of skin, clothing and tools by topical application, spray or wipes.
Formulations of the present invention can also be used to kill SARS, HBV, HPV, HIV and Example 11 Foot and mouth disease Foot and mouth disease is a rapidly spread aphthovirus infection of cattle and swine that causes fever and blistering. Treatement is by culling and disposing of infected animals. Formulations of the present invention could be topically applied to animals, people and related materials and tools to prevent the spread of the virus.
Example 12 Mastitis Bacterial infection cause inflammation, tenderness and pain in the udders of cows caused by S. agalactia, S. aureus, and/or mycoplasma. If untreated, mastitis can lead to destruction of the udder, lost productivity and infected milk. Current treatments include discinfecting teats with iodine after milking and culling animals with chronic cases, and treatment with topical and systemic antibiotics. Hygiene plays a significant role in preventing the disease. See the Merck Veterninary Manual, Eighth Edition, Forbes, January 1998; The Knoxville News-Sentinel, November 2002; UGA Animal & Dairy Science Annual Report 1995, Analysis of Mastitis Costs (Eberhart et al., 1987); Animal Pharm Reports - Mastitis: Challenges and Opportunities, 2002 (Executive Summary).
Formulations of the present invention can be used to topically treat the udder.
Example 13 Chemical sterilization Provide alternative to existing chemical sterilants, which cause safety concerns for healthcare lab workers and corrosion of instruments with motors, moving parts and nonmetal (e.g., plastic) interfaces. Devices to be sterilized could be soaked, washed, wiped, sprayed or flushed with compositions of the present invention.
Depending on the application, it may be necessary to use a sterile water or saline flush to remove any residual actives. Potential uses include any surface or device needing sterilization including but not limited to analytical equipment, robotic devices, vital signs monitoring lead wires and instruments, etc.
Example 14 Impregnated or coated patient care or personal hygiene devices Many medical devices or personal care products are impregnated with chlorhexidine gluocnate (CHG). CHG has been shown to cause hypersensitivity reactions when used in intravenous catheters, topical antimicrobial slcin dressings, and implanted antimicrobial surgical mesh. Formulations of the present invention are believed to be ultra mild and benign to the skin. Therefore, for.mulations of the present invention could be used to create an active barrier on commonly used devices in contact with patients.
Any medical device in contact with a patient can be potentially coated with the present formulations. For example, ventilator infections affect 35% of all mechanically-ventilated patients, are associated with 33%-35% mortality, and increase stays in ICUs by an average of 13 days. Ventilator tubing could be treated with formulations of the present invention to reduce or eliminate source of infection. Similarly, ECG lead sets and other reusable.
Example 15 Personal Care products Formulations of the present invention can be impregnated or coated on any personal care product in contact with skin or mucous membrane. Potential uses include device needing sterilization including but not limited to tampons and sanitary napkins, paper towels, toilet tissue, diapers, bandages, clothing, bed sheets, masks, surgical drapes, etc. For example, impregnated tampons could actively inhibit growth of group A
streptococcal bacteria that cause toxic shock syndrome.
Example 16 Condom coating Formulations of the present invention are also suitable for coating condoms to prevent spread of sexually transmitted bacterial viral or fungal diseases, including but not limited to gonnorhea, syphilis, HIV, and HPV. Such formulations could be added during manufacturing or incorporated into lubricating gels or lotions for application during use.
Care must be taken to choose excipients that are not damaging to the condom materials.
Example 17 Feminine hygiene products Products of the present invention can also be formulated as a douch, gel, lotion or foam to treat or prevent urinary tract infections ("UTIs"), toxic shock and prevent the spread of sexually transmitted diseases. The most common cause of UTIs is E.
coli bacteria. Using diaphragms, spermicide-coated condoms, and in-dwelling catheters can increase the risk of UTIs. Women often develop a UTI when they become sexually active because the bacteria from the vaginal area may be pushed into the urethra.
Formulations of the present invention can be coated on diaphrams, sponges prior to insertion.
Formulations in the form of a douche or wash can be used to cleanse the vaginal canal.
Formulations of the present invention could be packaged in individual dosage forms for use immediately prior to sexual contact and could include dosage forms suitable for application to diaphram or condom and suitable for disinfecting skin.
Example 18 Otic solutions Formulations of the present invention can be formulated for use in the ears to prevent or treat swimmers ear, and microbial ear infections.
Example 19 Body washes and Shampoos Formulations of the present inventions can be incorporated into therapeutic shampoos for use in humans or animals to treat diseases of the skin caused by microbial organisms.
The citation of any document is not to be construed as an admission that it is prior art with respect to the present invention. To the extent that any meaning or definition of a term in this written document conflicts with any meaning or definition of the term in a document cited herein, the meaning or definition assigned to the term in this written document shall govern.
While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention.
It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
FIELD OF THE INVENTION
The present invention relates to therapeutic antimicrobial coinpositions and methods that provide enhanced inunediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof. More specifically, the present invention relates to antimicrobial compositions comprising an organic acid or organic acid mixture, a specific, short-chain anionic surfactant having at least one of the following: a large, hydrophilic head group;
an unsaturated structure; and/or a branched structure, and therapeutic methods of using said compositions.
BACKGROUND OF THE INVENTION
Human and mammalian health is certainly impacted by the spread of microbial entities at home, school, work and in the environment generally. Indeed, viruses and bacteria continue to cause a variety of sicknesses and ailments, prompting high absenteeism in schools and places of employment. In the wake of widespread food poisoning and the like, the public has become even further concerned with sanitization, both of person and property. Consequently, those of skill in the art have focused their research endeavors on the identification and deployinent of suitable antimicrobial compositions, and specifically those that provide immediate and residual kill of microbes, with or without the use of water.
A comprehension of the vast benefits achieved via practice of the present invention requires an understanding of the various microbes against which the present compositions are effective. Bacteria found on human skin may be divided into two groups, namely, resident and transient bacteria. Resident bacteria are Gram-positive bacteria that establish as permanent microcolonies on the surface and outermost layers of the skin. Such bacteria play a fundamental role in preventing the colonization of other, more harmful bacteria and fungi. Transient bacteria are bacteria that are not part of the normal resident of the flora of the skin. Rather, transient bacteria are deposited when airborne contaminated material lands on the skin or when contaminated material is brought into physical contact with such bacteria. Transient bacteria are typically divided into two subgroups: Gram-positive and Gram-negative. Gram-positive bacteria include pathogens such as Staphylococcus aureus, Streptococcus pyogenes and Clostridiuni botulinun2. Gram-negative bacteria include pathogens such as Salnzonella, Escherichia coli, Klebsiella, Haemophilus, Pseudoinonas aeuginosa, Proteus and Shigella dysenteriae. Gram-negative bacteria are generally distinguished from Gram-positive bacteria via the existence of an additional protective cell membrane in the former, which often results in Gram-negative bacteria being less susceptible to conventional, topical antibacterial actives.
There exist several contemporary compositions and metliods for reducing and/or eliminating the formation of bacteria and/or viruses. For example, it is well known that the washing of hard surfaces, food (e.g. fruit or vegetables) and skin, especially the hands, with antimicrobial or non-medicated soap, is effective against viruses and bacteria.
Actually, removal of the viruses and bacteria is due to the surfactancy of the soap and the mechanical action of the wash procedure, rather than the function of an antimicrobial agent. Thus, it is recommended that people wash frequently to reduce the spread of viruses and bacteria. However, many conventional products and methods of sanitization, including washing, fail to address the dilemma of sanitization "on the go", that is to say, when a consuiner is removed from the benefit of running water. Those skilled in the art have attempted to resolve this dilemma via the incorporation of antimicrobial agents into disinfecting lotions, cleansing wipes and the like. Such articles reduce the need for water during or following the application of the subject composition.
Other conventional antimicrobial cleansing products include deodorant soaps, hard surface cleaners, and surgical disinfectants. These traditional, rinse-off antimicrobial products have been formulated to provide bacteria removal during washing.
A few such products, including antimicrobial soaps, have also been shown to provide a residual effectiveness against Gram-positive bacteria, but provide limited residual effectiveness against Gram-negative bacteria. By "residual effectiveness", it is meant that the subject antimicrobial controls microbial growth on a substrate by either preventing growth of microbes or engaging in continuous kill of microbes for some period of time following the washing and/or rinsing process. To address the dilemma of limited residual efficacy against Gram-negative bacteria, those skilled in the art have sought to incorporate high levels of alcohol and/or harsh surfactants into contemporary antimicrobial products, which have been shown to cause dryness and irritation to skin tissues.
Thus, there remains a substantial need to identify and deploy antimicrobial compositions that may be used by consumers "on the go"; provide immediate and residual kill of microbes with or without washing; and prevent dryness and irritation to skin following application. Despite providing a quasi solution to the dilemma of water availability, those skilled in the art have yet to identify antimicrobial compositions that address the problems associated with dryness and irritation to skin. In fact, attempts to resolve this dilemma have generally resulted in the adoption of aqueous-based antimicrobial formulas incorporating high levels of zwitterionic surfactants that are too weak to provide significant iinmediate or residual benefits. Others have attempted to address the dilemma of dryness or irritation to skin by incorporating cationic surfactants into antimicrobial compositions, which have been associated with adverse impacts on the environment and human health. Yet others still have attempted to resolve this dilenuna via the incorporation of long-chain anionic surfactants into antimicrobial coinpositions, which are intended to prevent skin tissue penetration. Nevertheless, such surfactants are often associated with poor phase stability in product, incompatibility with commercial antimicrobial agents, and low residual kill performance. Indeed, the identification of a balance between the factors of antimicrobial performance, skin mildness and water availability continues to be a key concern to those of skill in the antimicrobial art.
SUMMARY OF THE INVENTION
The present invention addresses and resolves all of the problems associated with the employment of conventional antimicrobial compositions and/or products.
Indeed, it has been surprisingly discovered that a composition incorporating an organic acid or organic acid mixture, a specific short-chain anionic surfactant having at least one of a large, hydrophilic head group; an unsaturated structure; and/or a branched structure;
constitutes a viable advancement and alternative in the realm of antimicrobial formulations. The antimicrobial compositions of the present invention are adapted for direct application to human skin, without causing dryness or irritation.
Moreover, the antimicrobial compositions of the present invention are designed for use with or without water, and provide immediate and residual effectiveness in either instance against a variety of viruses and bacteria, including rotavirus, rhinovirus, respiratory syricytial virus (RSV), coronavirus, Gram-positive and Gram-negative bacteria.
The specific, anionic surfactant of the present invention presents a particularly novel aspect of the present compositions. Those of skill in the art have generally relied upon the incorporation of longer chain (i.e. C12 to C16) anionic surfactants into antimicrobial compositions. Conventional surfactants, comparable to the acyl components found in the phospholipid matrix of the cell membrane of bacteria and virus, are thought to possess optimum antimicrobial activity with reduced skin tissue penetration. However, conventional anionic surfactants have been associated with low solubility under acidic conditions, poor compatibility with cationic antimicrobial agents, slow dissolution kinetics and limited residual antimicrobial performance.
Against the conventional wisdom in the art, the short chain anionic surfactants of the present invention comprise at least one of the following characteristics:
a large, hydrophilic head group; an unsaturated structure; and/or a branched structure.
Indeed, the surfactants of the present invention have traditionally been regarded as unsuitable for incorporation into an antimicrobial composition, based on the belief that such surfactants possess relatively low surface activity. Contrary to the traditional wisdom, it has been surprisingly discovered that the surfactants of the present invention deliver enhanced antimicrobial efficacy against rotavirus, rhinovirus, respiratory syricytial virus (RSV), coronavirus, Gram-negative bacteria and Gram-positive bacteria. More importantly, the large head group, unsaturated structure and/or branched structure of the present surfactants reduces or limits their tendency to penetrate skin tissue, while maximizing the immediate and residual effectiveness of the antimicrobial compositions in which they are incorporated. Further, the anionic surfactants of the present invention exhibit stability in an aqueous product at a low pH, are compatible with cationic antimicrobial agents and convey strong residual antimicrobial activity when the substrate on which they are applied is later inoculated with virus or bacteria.
Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof are described in commonly-assigned U.S. patent publication nos. US 2003/0235550 Al to Pan et al., December 25, 2003, US 2004/0001797 Al to Saud et al., January 1, 2004 and in published PCT
application WO 2004/000016 A2 to Pan et al., December 31, 2003.
These antimicrobial compositions comprise an organic acid or organic acid mixture, a specific short-chain anionic surfactant with branching or a large head group, and, optionally, a calcium ion scavenger and/or anti-foam agents.
In accordance with a first aspect of the present invention, therapeutic antimicrobial compositions and methods are disclosed. In one aspect, the present antimicrobial compositions comprise an organic acid or organic acid mixture, a specific, short-chain anionic surfactant mixture are disclosed. Suitable anionic surfactants for use in the context of the present invention comprise a chain length of from about C4 to C12 and at least one of the following characteristics: a large, hydrophilic head group; an unsaturated structure; and/or a branched structure. In yet another aspect, the antimicrobial compositions disclosed herein optionally further comprise a calcium ion scavenger and/or an anti-foam agent. The therapeutic methods and compositions of the present invention are adapted to provide immediate and residual Itill of numerous bacteria and viruses, with or without the use of water and without causing dryness or irritation to skin.
In accordance with another aspect of the present invention, there is provided a method of treating or provenfng a m=icarobial caused infection in a patient in need thereof, said method characterized by comprising the step of administering an efÃeotive amount of antimicrobial composition comprising: a. from 0.2% to 70% of an organic acid; and b. from 0.1 % to 40% of an anionic surfactant mixture having (i) a Iinear alkyl ohain length of from C4 to C12 and a total head group size of at least 4 Angstroms; and/or (n) a bxanehed alkyl chain length of from C4 to C12; and/or (iii) a branched alkyl chain length of from C4 to C12 and a total head group size of at least 4 Angstroms;
wherein said eomposition is characterized by a pH of from 2.0 to 4.5.
In accordance with another aspect of the present invention, there is provided a method of disinfecting devices characterized by comprising treating a device with an effective amount of an antimicrobial composition comprising: a. from 0.2%
to 70% of an organic acid; and b. from 0.1% to 40 /fl of an anionic surfactant mixture having i. a linear alkyl chain length of from C4 to C12 and a total head group size of at least 4 Angstroms; and/or ii. a branched alkyl chain length of from C4 to C12; and/or iii. a branched alkyl chain length of from C4 to Ci2 and a total head group size of at least 4 Angstroms; wherein said composition is eharacterized by a pH of from 2.0 to 4.5.
5a In accordance with another aspect of the present invention, there is provided a method of preventing infections originating in medical devices in a patient in need thereof characterized by comprising disinfecting the devices with an effective amount of an antimicrobial composition comprising: a. from 0.2% to 70% of an organic acid; and b.
from 0.1% to 40% of an anionic surfactant mixture having i. a linear alkyl chain length of from C4 to CIZ and a total head group size of at least 4 Angstroms; and/or ii.
abranched alkyl chain length of from C4 to C12; and/or iii. a branched alkyl chain length of from C4 to C12 and a total head group size of at least 4 Angstroms; wherein said composition is characterized by a pH of froan 2.0 to 4.5.
These and other objects, features, and advantages will become apparent to those of ordinary skill in the art from a reading of the following detailed description and the appended claims. All percentages, ratios and proportions herein are by weight, unless otherwise specified. All temperatures are in degrees Celsius (0 C) unless otherwise specified.
DETAILED DESCRIPTION Op T'HE INVENTION
Antimicrobial compositions that provide enhanced immediate and residual anti-viral and antibacterial efficacy against rhinovirus, rotavirus, Gram-positive bacteria, Gram-negative bacteria and combinations thereof are described in commonly-assigned U.S. patent publication nos. US 2003/0235550 Al to Pan et al., December 25, 2003, US 2004/0001797 Al to Saud et al., January 1, 2004 and in published PCT
application WO 2004/000016 A2 to Pan et al., December 31, 2003.
These compositions were stated to have effica.cy against gram negative and gram positive bacteria and also against viruses. We believe that certain formulations of these short chain, big head surfactant based antimicrobial compositions will be effective against a wide variety of pathenogenic agricultural organisms including but not limited to citrus canker.
These antimicrobial compositions comprise an organic acid or organic acid mixture, a specific short-chain anionic surfactant with branching or a large head group, and, optionally, a calcium ion scavenger and/or anti-foam agents. For therapeutic use the formulations require in addition to the surfactant, an organic acid acid and a nonionic agent. Preferred is to use C8-AGS as the surfactant, pyrrolidone carboxylic acid as the organic acid and ethylhexyl glycerol ether (EHOP) as the non-ionic agent. One of skill in the art will recognize that other agents as disclosed in U.S. patent publication nos. US
2003/0235550 Al to Pan et al., December 25, 2003, US 2004/0001797 Al to Saud et al., January 1, 2004 or published PCT application WO 2004/000016 A2 to Pan et al., December 31, 2003 may be substituted. Preferred are compositions having greater than about 0.50% C8AGS with most preferred compositions containing at least 1.25%
and a pyrrolidone carboxylic acid content of greater than or equal to 2.0%.
One of skill in the art will readily recognize that other active ingredients can be included to provide different properties or to improve the effectiveness of the present compositions against specific organisms. When adding other actives, the concentration of surfactants, acids and/or non-ionic agents would also be modified to provide the degree of activity desired. For example, Parachlorometaxylenol (PCMX), a known antimicrobial may be added to provide another broad spectrum antimicrobial. For example when adding PCMX, it is possible to reduce the amount of C8AGS below 1%
concentration by weight.
Five formulations of antimicrobial compositions were created having the active agents set forth in Table 1. Water makes up the balance of the formulation.
These formulations were made in accordance with U.S. patent publication nos. US
2003/0235550 Al to Pan et al., December 25, 2003, US 2004/0001797 Al to Saud et al., January 1, 2004 and in published PCT application WO 2004/000016 A2 to Pan et al., December 31, 2003.
Table 1.
Formula Active Component (WR M H KS KSM
C8-AGS 0.50 1.25 2.00 0.60 1.00 Coco Sulfofatty Acid 0.40 Gluconic Acid 2.00 P o lutamic Acid (PCA) 2.00 15.00 3.50 3.00 Succinic Acid 1.50 2.00 Ethylhexyl Glyceryl Ether EHOP 0.55 1.00 0.50 0.50 Parachlorometaxylenol (PCMX) 0.35 0.50 Potassium Sorbate 0.10 Formulation The composition of the present invention may be formulated for use in any manner lrnown to one of skill in the art. Formulations for topical, mucosal and aerosol delivery of drugs are taught in Modern Pharmaceutics by Gilbert S. Banker (Editor), Christopher T. Rhodes (Editor) Marcel Dekker; 4th edition (June 15, 2002) ISBN:
0824706749. Reference is also made to the International Journal of Pharmaceutical Compounding which can be accessed at www.ijpc.com. These sources teach and describe the basics of pharmaceutical compounding. One of skill in the art will know how to take the active ingredients of the present invention and formulate them for delivery. Such formulations may take the form. of lotions, ointments, gels, creams, drops washes, pastes, suppositories, lozenges, mouthwashes, gargles, douches, foams, surface coatings, liposomes, microspheres and transdermal patches.
One of skill in the art will appreciate that the activity of the present compositions can be affected through the selection of excipients to provide varying degree of skin penetration or to control release. Activity of the present formulations can be increased by occlusion of the skin after application with a suitable bandage or wrap. One of skill in the art will also recognize that persistent action can be increased by use of controlled release technologies which delay release of active over time.
The formulations contemplated herein can also be coated or otherwise incorporated into medical devices such as wipes, sponges, bandages, surgical drapes, hospital gowns, surgical gowns. Formulations can be developed that are suitable for disinfecting medical devices. Such formulations could be in the form of a liquid which could be used for spraying onto surfaces, soaking of devices, pumping through devices or incorporated into wipes for decontaminating a surface.
Testinll The formulations described above were tested for Minimum Bactericidal Dilution and Residual efficacy against C. Albicans, E. Coli, S. marcesens, Metlaicillin Resistant Staphylococcus aureus, and E. faecalis, Minimum Bactericidal Dilution.
Various formulations as set out in Table 2 below were tested for Minimum Bactericidal Dilution. Organisms to be tested were grown on slants and transferred to an agar plate by streaking to form a lawn. Colonies are scraped off the agar plates using a sterile innoculating loop and suspended in phosphate buffered solution (PBS) and diluted to 5 x 106 CFU/ml.
Table 2 MINIMUM BACTERICIDAL DILUTION
HTR Test C. faecalis E. coli P. S. S. aureus S. aureus albicans aeruginosa marcescens (MRSA) # Article 10231 51299 ~~E) 11229 15442 14756 6538 33591 0.1%
EHOP, 1 1.25% Inhibition 1:8 1:8 1:16 1:2 Undiluted Undiluted AGS, 8.5% PCA, 1 % EHOP, 2 A0.5 GS, Inhib'tion 1:2 1:16 1:8 1:4 Inhib tion Undiluted 2% PCA
0.1%
3 EHOP, 2% No 1:4 1:16 1:16 1:4 1:2 1:2 AGS, Inhibition 15% PCA
MINIMUM BACTERICIDAL DILUTION
C. E. P. S. S.aureus HTR Test faecalis E. coli S. aureus albicans aeruginosa marcescens (MRSA) # Article 10231 (VRE) 11229 15442 14756 6538 33591 0.1%
EHOP, 4 0.5% Inhibition Undiluted Undiluted 1:2 1:8 Undiluted 1:4 AGS, 15%
PCA
0.1%
EHOP, 2% No 1:4 1:2 1:8 1:8 1:2 1:8 AGS, Inhibition 2% PCA
0.55% 1:1024 EHOP, 1:4 6 1.25% hihiliirion 1:32 1:4 1:8 Undiluted 1:16 AGS, 1:4 15% PCA
0.1%
EHOP, 7 0.5% Inhibition Undiluted 1:8 1:8 Undiluted Inhibition Inhibition AGS, 2% PCA
1% EHOP, 8 2% AGS, Undiluted 1:32 1:32 1:64 1:64 1:16 1:2 15% PCA
1% EHOP, No 9 2% AGS, Inhibition 1:16 1:16 1:8 1:8 1:16 1:16 2% PCA
0.55%
EHOP, 2% Undiluted 1:16 1:32 1:4 1:2 1:4 1:8 AGS, 8.5% PCA
1% EHOP, 11 1.25% Undiluted Undiluted 1:2 1:4 1:4 1:4 1:8 AGS, 8.5% PCA
0.55% 1:16 EHOP, 1:4 12 1.25% Undiluted 1:2 1:8 1:2 1:4 1:8 AGS, 1:2 8.5% PCA
0.55%
EHOP, 13 1.25% Inhibition 1:16 1:8 1:4 1:4 1:4 1:4 AGS, 2%
PCA
0.55%
EHOP, 14 0.5% Inhibition 1:2 Undiluted 1:8 1:4 Undiluted Undiluted AGS, 8.5% PCA
1 % EHOP, 0.5% 15 AGS, Inhibition Undiluted Undiluted 1:4 1:16 Undiluted Undiluted 15% PCA
0.55% 1:32 EHOP, 1:4 16 1.25% Inhibition 1:8 1:16 1:32 Undiluted 1:2 AGS, Undiluted 8.5% PCA
0.55% 1:2048 EHOP, 1:4 17 1.25% Inhibition 1:32 1:8 1:32 1:8 Undiluted AGS, 1:8 8.5% PCA
0.55% 1:256 1:32 EHOP, 1:2 1:4 18 1.25% Inhibition 1:16 1:8 1:4 1:8 AGS, 1:2 1:4 8.5% PCA
0.55% 1:4 1:256 EHOP, 1:2 1:4 19 1.25% Inhibition 1:8 1:2 Undiluted 1:2 AGS, 1:2 1:4 8.5% PCA
0.55% 1:2048 EHOP, 1:16 1.25% Inhibition 1:16 1:32 1:2 Undiluted 1:2 AGS, 1:4 8.5% PCA
21 ChloraPrep 1:4 1:4 1:64 1:2 1:2 1:32 1:8 In Vitro Time Kill Candida Albicans was cultured under appropriate conditions. (current USP
procedures for culturing organisms is appropriate.) Incubation period varies (typically 120 hours at 25 C +/- 1 C) to a density of between 1.0E+06 - 1.0E+07 CFUs/mL.
Actual CFUs/mL of starting cultures were determined by serially diluting and plating an aliquot (typically plate 10-6, 10-5, 10"4 , 10-3, 10-2 dilutions). A 50 l aliquot of the yeast culture was pipetted into 5.OmL of the antimicrobial solution(s) in a sterile scintillation vial (organisms: solution ratio = 1:100) and mixed thoroughly by vortexing. Test inoculum level was - 1.0E+04-1.0E+05 CFUs/mL. At the predetermined time point(s), 1 min, 5 min, and 10 min, a 0.5mL aliquot of the inoculated antimicrobial solution is pipetted into 4.5mL of Dey/Engley (D/E) neutralizing broth (ratio = 1:10) and mixed by vortexing. An aliquot of the neutralized sample including yeast was plated onto a Sabouaud Dextrose Agar (SDA) plate using standard pour plate techniques. The SDA plates were incubated at 25 C+/- 1 C for 5 days (-120 hours) and CFU's are counted. CFUs/mL for organism cultures are calculated and compared to CFUs/mL for antimicrobial solutions to determine the log reductions.
Residual Skin Testing Residual skin testing was perfonned by evenly coating the surface of a skin patch with 20 1 of the active solution. Skin samples were allowed to evaporate for 1 minute, 15 minutes , 60 minutes, 120 minutes, 240 minutes,360 minutes, 480 minutes, and 14 hours with the lid off the Petri plate. At the appropriate time point, skin sainples were inoculated with 10 1 of a 1:10 dilution of the 18-hour microbial suspension (-1.0E+08 CFUs/mL), evenly covering the entire area and the sample recovered and allowed to sit 5 minutes. At this time the skin was extracted using sterile forceps and placed in a steril centrifuge tube.
Containing lOml of a sampling solution and vortexed for 30 seconds. An aliquot of the extracted sample containing any microbials from the skin was plated onto a trypticase soy agar plate using a spiral plater (typically 50 1 in exponential mode).
The agar plates were incubated at 37 C overnight (-18 hours) and CFUs are counted.CFUs/mL established by Baseline Count are calculated and compared to CFUs/inL for antimicrobial/bacterial solutions to determine the log reductions.
The Baseline Count was achieved by evenly spreading 10 1 of the diluted bacterial suspension on a square of the Skin and processed in accordance with the above procedure, except no active solution was added.
Test results Anti-Fungal/Yeast Activity Formulas R, M, H, KS and KSM were tested against Candida albicans and compared for activity with Chloraprep. The antifungal properties of these formulations were previously untested and unknown. In vitro time kill testing was performed as described above. The result of the testing are set forth in Table 3.
Table 3 In vitro time-kill of C. albicans 10231 Minutes of contact time (log reduction from log 5.0 titer) Formula sample 1 5 10 ChloraPrep (70% alcohol + 2% CHG) 4.8 4.8 4.8 KSM 4.8 4.8 4.8 M 1.3 4.8 4.8 RID 0.3 0.9 1.0 Residual Skin efficacy testing against C. albicans was performed as set forth above. The data are set forth in Table 4 below.
Table 4 Candida albicans (C. albicans 10231) Residual Efficacy Chlora- RID M H KS KSM
Log Reduction prep 1 min 3.6 0.8 2.3 3.4 3.6 3.6 15 min 2.2 1.1 2.7 3.9 3.6 3.6 60 min 2.5 0.9 2.9 3.9 3.6 3.6 120 min 1.8 2.1 3.2 3.9 3.6 3.6 240 min 1.1 0.2 2.7 3.9 3.6 3.6 The above data show that medically acceptable strengths of RID kill candida.
Faster kill, but not more residual activity can be obtained by adding known broad spectrum antimicrobial (PCMX).
E.Coli Formulas R, M, H, KS and KSM were tested against E. coli and compared with Chloraprep. Residual Skin efficacy testing against E.Coli was performed as set forth above. The data are set forth in Table 5 below.
Table 5 E. coli (E. coli 11229) Residual efficacy testing.
Chlora- RID M H KS KSM
Log Reduction prep 1 min 4.6 0.6 4.6 4.6 4.6 4.6 15 min 4.5 2.7 4.6 4.6, 3.7 4.5 60 min 4.1 4.5 4.6 4.6 4.6 4.6 120 min 3.3 3.7 4.6 4.2 4.6 4.6 240 min 3.9 4.0 4.6 4.1 4.6 4.6 Serratia marcesens (S. marcesens 14756) Formulas R, M, H, KS and KSM were tested against S. marcesens and compared with Chloraprep. Residual Skin efficacy testing against S. marcesens was performed as set forth above. The data are set forth in Table 6 below.
Table 6 S. marcesens 14756 Residual Efficacy Results Chlora- RID M H KS KSM
Log Reduction prep 1 min 1.8 0.1 3.6 6.0 5:1 5.1 15 min 0.7 0.1 3.6 6.0 5:1 5.1 60 min 2.0 0.9 2.0 6.0 4.5 5A
120 min 1.1 0.0 3.7 ' 6.0 5.1 5.1 240 min 1.0 0.2 2.8 6.0 5.1 5.1 Methicillin Resistant Staplzylococcus aureus (MRSA) Formulas R, M, H, KS and KSM were tested against MRSA and compared with Chloraprep. Residual Skin efficacy testing against MRSA was performed as set forth above. The data are set forth in Table 7 below.
Table 7 MRSA (S. aureus 33591) Residual Efficacy Results Chlora- R M H KS KSM
Log Reduction prep 1 min 5.5 1.3 0.9 4.9 5.1 5.1 15 min 1.4 0.2 0.6 3.9 5.0 4.9 60 min 2.7 0.1 0.6 2.9 5.8 4.9 120 min 3.9 0.3 1.3 4.0 4.8 4.5 240 min 3.7 0.4 1.7 4.6 5.0 4.8 Vancomycin Resistant Enterococci (VRE) Formulas R, M, H, KS and KSM were tested against E. faecalis and compared with Chloraprep. Residual Skin efficacy testing against E. faecalis was performed as set forth above. The data are set forth in Table 8 below.
Table 8VRE (E. faecalis 51299) Residual Efficacy Results Chlora- RID GMP / GMP / GMP / GMP /
Log Reduction prep M H KS KSM
1 min 4.3 0.5 4.7 4.7 4.8 4.8 15 min 1.1 1.3 4.5 4.7 4.8 4.4 60 min 1.5 2.0 4.7 4.7 4.8 4.8 120 min 1.7 2.8 4.7 4.7 4.6 4.8 240 min 3.2 0.6 4.7 4:7 4.8 4.8 Theraueutic examples Example 1 Acne Acne is a common disease affecting millions of Americans every year. The condition is characterized by lesions or pimples caused by infection with P.
acnes and/or P. granulosum bacteria. Common treatment is with topical retinoids, steroids, antibiotics, and topical counterirritants such as sulfur, benzoyl peroxide and/or alcohol and/or use of systemic antibiotics.
Acne could be treated and its spread prevented by topical administration of the formulations disclosed herein in a bar, pledget, lotion, gel, or cream.
Example 2 Atopic dermatits Atopic dermatits is a condition affecting 3-10% of the US. It most commonly affects young children and is characterized by scaly patches, small vescicles, excoriations, crusting, impetiginization caused by the presence of S. aureus in the horny layer of epidermis. Current treatment is with emollients, topical corticosteroids and/or topical or oral antihistamines. Severe cases may also be treated with UV-B phototherapy, psoralen + UVA, oral corticosteroids.
Antimicrobial compositions of the type disclosed herein have been shown to be useful in killing S. aureus bacteria. Atopic dermatits could be treated and its spread prevented through formulations of the present invention for topical administration in a soap, pledget, lotion, gel, or cream.
Example 3 Blepharitis Blepharitis causes lifelong chronic inflammation of eyelids is caused by Staphylococcus or yeast colonization on eyelid margins. Transmission is possible by touch. Current treatment includes use of warm compresses and lid scrubs. See, Harrison's Principals of Internal Medicine, 15th Edition.
Antimicrobial compositions of the type disclosed herein have been shown to be useful in killing S. aureus bacteria. Blepharitis could be treated and its spread prevented through formulations of the present invention for topical administration in ointments, drops, or other fomulations suitable for ocular administration.
Example 4 Diaper Rash/Dermatitis Diaper rash is caused by irritation from contact with urine and stool that leads to redness and breakdown of skin. Frequently accompanying common diaper rash is diaper dermatitis. Diaper dermatitis is most frequently caused by strains of the fungus Candida.
Secondary bacterial infections of staphylococcus and enterobacter are also possible.
Current treatments include zinc oxide cream and topical antifungal agents. It is believe that 20% of infants within first 2 years Only 10% of cases are reported. See Cecil Textbook of Medicine 22nd Edition 2004.
Treatment and/or prevention of the primary candida infection should be possible by use of the present forinulations in by application. Antimicrobial compositions of the type disclosed herein have been shown to be useful in killing candida, S.
aureus and enterobacter bacteria. Diaper rash and dermatitis could be treated and its spread prevented through formulations of the present invention for topical administration in a bar, pledget, lotion, gel, ointment or cream.
Example 5 Fungal skin infections A variety of skin infections are cause by fungal infection Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, demratophytes, yeasts and molds. Athlete's foot (tinea pedis) and nail fungus being among the more common.
Athletes foot is commonly treated with antifungal creams, sprays and powders, oral medications. Nail fungus and toenail fungus in particular are more difficult to treat due to the protective nail. Common OTC nail creams and ointments are relatively ineffective.
Oral antifungals such as itraconazole offer good efficacy but are expensive.
See Cecil Textbook of Medicine 22nd Edition 2004.
Fungal skin infections could be treated and its spread prevented through formulations of the present invention for topical administration in a bar, pledget, lotion, gel, ointment or cream.
Example 6 Impetigo Impetigo is the most common bacterial skin infection in children. This disease is characterized by various skin lesions, including bulla, vesicles and blisters caused by S.
aureus and/or Streptococcus. Impetigo contagiosa is the most common form, first appearing as blisters or red sores. Eventually, the blisters rupture and ooze a fluid that forms a cntst over the affected area. The sores may tend to itch, but generally do not cause pain although there may be swollen lymph nodes in the affected area.
Impetigo contagiosa is highly contagious and is readily spread to other parts of the body through touching or scratching the sores. It is also readily spread to others through personal contact and by sharing items with an infected person.
Impetigo contagiosa is readily treated through improved hygiene and topical antiobiotic ointments and/or oral antibiotics. In most cases, healing begins within three days of treatment. Though it is seldom serious, this infection can sometimes lead to complications, such as scarring, if left untreated. See Cecil Textbook of Medicine 22nd Edition 2004 and MayoClinic.com.
We believe that formulations of the present invention will treat and prevent impetigo by killing and stopping the txansfer of S. aureus and other bacteria.
Impetigo could be treated and its spread prevented through formulations of the present invention for topical administration in a bar, pledget, lotion, gel, ointment or cream.
Example 7 Thrush Oropharyngeal candidiasis (OPC) or thrush is a candida fungal infection of the mouth, throat and/or tongue. It is common in newborns, infants, and older adults, but can occur at any age. Thrush due to T-cell dysfunction is the most common opportunistic infection in HIV affecting 80-90% of all patients with advanced stages of HIV
infection.
Thrush is commonly treated with nonprescription and prescription antifungals and in HIV
infected patients through the concommitant use of oral azoles, and possibly intrvenous amphotericin in severe refractory cases. See Cecil Textbook of Medicine 22nd Edition 2004.
Thrush can be difficult to treat in infants due to the many places that candida species can hide. Reinfection may occur from toys, pacifiers, mother's breast, etc.
Because of the fast rate at which yeast multiply, Current therapies includ treatment with nystatin 4-8 or more times per day. The residual action of the present compositions should reduce frequency of application and improve rate of recovery by reducing ability of candida to hide and spread. Preferential application is topical application to mother's breasts, infant pacifiers and to swab affected areas of the mouth. Adults may also be treated in the same manner as well as with mouthwashes and gargles.
Example 8 Trachoma Trachoma is chronic conjuctival inflammation cause by C. trachomatis. It is conunon in developing world countries and is the cause of at least 4 million cases of blindness and 5 million cases of low vision. Current treatrnent is through surgury of the eyelid and topical antibiotics. See Cecil Textbook of Medicine 22nd Edition 2004.
Formulations of the present invention can be applied as drops or ointment to the eyes to treat and/or prevent spread of trachoma.
Example 9 Warts Warts are hard growths on skin cause by the Human papillomavirus. The primary treatment means is topical treatmentwith salicylic acid. See Cecil Textbook of Medicine 22nd Edition 2004.
Warts could be treated with the antiviral compositions of the present application through any topical formulation and/or use of treated bandages.
Example 10 Avian Flu/Influenza Avian flu is a highly infections and frequently fatal virus caused by Influenza A..
Its fatality rate is 33% vs. 10% for SARS. Treatment consists of destroying infected birds and decontaminating tools and clothing that may have come in contact with the virus using bleach solutions. See the World Health Organization Avian Influenza Fact Sheet 2004 available at http://www.who.int/mediacentre/factsheets/avan influenza/en/.
Formulations of the present invention could be administered to affected livestock via sprays to treat and prevent the spread of outbreaks. The present invention can also be used for decontamination of skin, clothing and tools by topical application, spray or wipes.
Formulations of the present invention can also be used to kill SARS, HBV, HPV, HIV and Example 11 Foot and mouth disease Foot and mouth disease is a rapidly spread aphthovirus infection of cattle and swine that causes fever and blistering. Treatement is by culling and disposing of infected animals. Formulations of the present invention could be topically applied to animals, people and related materials and tools to prevent the spread of the virus.
Example 12 Mastitis Bacterial infection cause inflammation, tenderness and pain in the udders of cows caused by S. agalactia, S. aureus, and/or mycoplasma. If untreated, mastitis can lead to destruction of the udder, lost productivity and infected milk. Current treatments include discinfecting teats with iodine after milking and culling animals with chronic cases, and treatment with topical and systemic antibiotics. Hygiene plays a significant role in preventing the disease. See the Merck Veterninary Manual, Eighth Edition, Forbes, January 1998; The Knoxville News-Sentinel, November 2002; UGA Animal & Dairy Science Annual Report 1995, Analysis of Mastitis Costs (Eberhart et al., 1987); Animal Pharm Reports - Mastitis: Challenges and Opportunities, 2002 (Executive Summary).
Formulations of the present invention can be used to topically treat the udder.
Example 13 Chemical sterilization Provide alternative to existing chemical sterilants, which cause safety concerns for healthcare lab workers and corrosion of instruments with motors, moving parts and nonmetal (e.g., plastic) interfaces. Devices to be sterilized could be soaked, washed, wiped, sprayed or flushed with compositions of the present invention.
Depending on the application, it may be necessary to use a sterile water or saline flush to remove any residual actives. Potential uses include any surface or device needing sterilization including but not limited to analytical equipment, robotic devices, vital signs monitoring lead wires and instruments, etc.
Example 14 Impregnated or coated patient care or personal hygiene devices Many medical devices or personal care products are impregnated with chlorhexidine gluocnate (CHG). CHG has been shown to cause hypersensitivity reactions when used in intravenous catheters, topical antimicrobial slcin dressings, and implanted antimicrobial surgical mesh. Formulations of the present invention are believed to be ultra mild and benign to the skin. Therefore, for.mulations of the present invention could be used to create an active barrier on commonly used devices in contact with patients.
Any medical device in contact with a patient can be potentially coated with the present formulations. For example, ventilator infections affect 35% of all mechanically-ventilated patients, are associated with 33%-35% mortality, and increase stays in ICUs by an average of 13 days. Ventilator tubing could be treated with formulations of the present invention to reduce or eliminate source of infection. Similarly, ECG lead sets and other reusable.
Example 15 Personal Care products Formulations of the present invention can be impregnated or coated on any personal care product in contact with skin or mucous membrane. Potential uses include device needing sterilization including but not limited to tampons and sanitary napkins, paper towels, toilet tissue, diapers, bandages, clothing, bed sheets, masks, surgical drapes, etc. For example, impregnated tampons could actively inhibit growth of group A
streptococcal bacteria that cause toxic shock syndrome.
Example 16 Condom coating Formulations of the present invention are also suitable for coating condoms to prevent spread of sexually transmitted bacterial viral or fungal diseases, including but not limited to gonnorhea, syphilis, HIV, and HPV. Such formulations could be added during manufacturing or incorporated into lubricating gels or lotions for application during use.
Care must be taken to choose excipients that are not damaging to the condom materials.
Example 17 Feminine hygiene products Products of the present invention can also be formulated as a douch, gel, lotion or foam to treat or prevent urinary tract infections ("UTIs"), toxic shock and prevent the spread of sexually transmitted diseases. The most common cause of UTIs is E.
coli bacteria. Using diaphragms, spermicide-coated condoms, and in-dwelling catheters can increase the risk of UTIs. Women often develop a UTI when they become sexually active because the bacteria from the vaginal area may be pushed into the urethra.
Formulations of the present invention can be coated on diaphrams, sponges prior to insertion.
Formulations in the form of a douche or wash can be used to cleanse the vaginal canal.
Formulations of the present invention could be packaged in individual dosage forms for use immediately prior to sexual contact and could include dosage forms suitable for application to diaphram or condom and suitable for disinfecting skin.
Example 18 Otic solutions Formulations of the present invention can be formulated for use in the ears to prevent or treat swimmers ear, and microbial ear infections.
Example 19 Body washes and Shampoos Formulations of the present inventions can be incorporated into therapeutic shampoos for use in humans or animals to treat diseases of the skin caused by microbial organisms.
The citation of any document is not to be construed as an admission that it is prior art with respect to the present invention. To the extent that any meaning or definition of a term in this written document conflicts with any meaning or definition of the term in a document cited herein, the meaning or definition assigned to the term in this written document shall govern.
While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention.
It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
Claims (11)
1. Use of an effective amount of an antimicrobial composition for treatment or prevention of a microbial caused infection in a patient in need thereof, said composition comprising:
a. from about 0.2% to about 70% by weight of an organic acid; and b. from about 0.1% to about 40% by weight of an anionic surfactant mixture having (i.) a linear alkyl chain length of from C4 to C12 and a total head group size of at least about 4 Angstroms; and/or (ii.) a branched alkyl chain length of from C4 to C12; and/or (iii.) a branched alkyl chain length of from about C4 to about C12 and a total head group size of at least about 4 Angstroms; wherein said composition is characterized by a pH of from about 2.0 to about 4.5.
a. from about 0.2% to about 70% by weight of an organic acid; and b. from about 0.1% to about 40% by weight of an anionic surfactant mixture having (i.) a linear alkyl chain length of from C4 to C12 and a total head group size of at least about 4 Angstroms; and/or (ii.) a branched alkyl chain length of from C4 to C12; and/or (iii.) a branched alkyl chain length of from about C4 to about C12 and a total head group size of at least about 4 Angstroms; wherein said composition is characterized by a pH of from about 2.0 to about 4.5.
2. Use of a composition in the manufacture of a medicament for treatment or prevention of a microbial caused infection, said composition comprising:
a. from about 0.2% to about 70% by weight of an organic acid; and b. from about 0.1% to about 40% by weight of an anionic surfactant mixture having (i.) a linear alkyl chain length of from C4 to C12 and a total head group size of at least about 4 Angstroms; and/or (ii.) a branched alkyl chain length of from C4 to C12; and/or (iii.) a branched alkyl chain length of from C4 to C12 and a total head group size of at least about 4 Angstroms; wherein said composition is characterized by a pH of from about 2.0 to about 4.5.
a. from about 0.2% to about 70% by weight of an organic acid; and b. from about 0.1% to about 40% by weight of an anionic surfactant mixture having (i.) a linear alkyl chain length of from C4 to C12 and a total head group size of at least about 4 Angstroms; and/or (ii.) a branched alkyl chain length of from C4 to C12; and/or (iii.) a branched alkyl chain length of from C4 to C12 and a total head group size of at least about 4 Angstroms; wherein said composition is characterized by a pH of from about 2.0 to about 4.5.
3. The use according to claim 1 or 2, wherein said anionic surfactant is selected from alkyl glyceryl sulfonate, alpha sulfo fatty acid, alkyl phosphonate, branched alkyl sulfonate, branched alkyl benzene sulfonate, secondary alkyl sulfate, mono ester of alkyl sulfosuccinic acid, alkyl isethionate, alkyl amidosulfonate, and combinations thereof.
4. The use according to any one of claims 1 to 3, wherein said anionic surfactant is substituted with a sulfonate, sulfate or phosphonate group.
5. The use according to any one of claims 1 to 4, wherein said organic acid is selected from pyroglutamic acid, adipic acid, gluconic acid, gluconolactone acid, glutamic acid, glutaric acid, glycolic acid, tartaric acid, ascorbic acid and combinations thereof.
6. The use according to any one of claims 1 to 5, wherein the antimicrobial composition further comprises a nonionic agent.
7. The use according to claim 6, wherein said nonionic agent is selected from 1-(2-ethylhexyl)glycerol ether, octyl glycerol ether, 2-(2-ethylhexylxoxy)propanol, octyloxy-propanol, 1-(2-ethylhexyloxy) ethanol, octyloxy ethanol, 1,2-hexylenediol, 1,2-cyclohexanedimethanol, isopropyl glycerol ether and combinations thereof.
8. The use according to claim 6, wherein said nonionic agent is present in an amount of about 0.1% to about 10% by weight of total composition.
9. The use according to any one of claims 1 to 8, wherein the microbial infection is caused by at least one of the following: Yeast, molds, bacteria or viruses.
10. The use according to claim 9, wherein the yeast is a Candida strain.
11. The use according to claim 9, wherein the bacteria is either a gram negative or a gram positive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002686815A CA2686815A1 (en) | 2004-04-26 | 2005-04-26 | Therapeutic antimicrobial compositions and methods |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US56531104P | 2004-04-26 | 2004-04-26 | |
| US60/565,311 | 2004-04-26 | ||
| PCT/US2005/014279 WO2005105070A2 (en) | 2004-04-26 | 2005-04-26 | Therapeutic antimicrobial compositions and methods |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002686815A Division CA2686815A1 (en) | 2004-04-26 | 2005-04-26 | Therapeutic antimicrobial compositions and methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2562329A1 CA2562329A1 (en) | 2005-11-10 |
| CA2562329C true CA2562329C (en) | 2009-12-22 |
Family
ID=35149038
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002686815A Abandoned CA2686815A1 (en) | 2004-04-26 | 2005-04-26 | Therapeutic antimicrobial compositions and methods |
| CA002562329A Active CA2562329C (en) | 2004-04-26 | 2005-04-26 | Therapeutic antimicrobial compositions and methods |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002686815A Abandoned CA2686815A1 (en) | 2004-04-26 | 2005-04-26 | Therapeutic antimicrobial compositions and methods |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20050271711A1 (en) |
| EP (2) | EP2298351A3 (en) |
| JP (1) | JP2007534701A (en) |
| CN (1) | CN1946428A (en) |
| AR (1) | AR052399A1 (en) |
| AT (1) | ATE492272T1 (en) |
| AU (1) | AU2005237546B2 (en) |
| BR (1) | BRPI0510327A (en) |
| CA (2) | CA2686815A1 (en) |
| DE (1) | DE602005025466D1 (en) |
| ES (1) | ES2360803T3 (en) |
| IL (1) | IL178894A0 (en) |
| MX (1) | MXPA06012442A (en) |
| NO (1) | NO20065457L (en) |
| WO (1) | WO2005105070A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11026422B2 (en) | 2017-09-26 | 2021-06-08 | Ecolab Usa Inc. | Acid/anionic antimicrobial and virucidal compositions and uses thereof |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050260243A1 (en) * | 2004-04-26 | 2005-11-24 | The Procter & Gamble Company | Method of treating microbial plant diseases |
| CA2588782A1 (en) * | 2004-12-09 | 2006-06-15 | The Dial Corporation | Compositions having a high antiviral and antibacterial efficacy |
| US20090012174A1 (en) * | 2004-12-09 | 2009-01-08 | The Dial Corporation | Compositions Having a High Antiviral and Antibacterial Efficacy |
| CA2588802A1 (en) * | 2004-12-09 | 2006-06-15 | The Dial Corporation | Compositions having a high antiviral and antibacterial efficacy |
| EP1830638A2 (en) * | 2004-12-09 | 2007-09-12 | The Dial Corporation | Compositions having a high antiviral and antibacterial efficacy |
| US9629361B2 (en) | 2006-02-09 | 2017-04-25 | Gojo Industries, Inc. | Composition and method for pre-surgical skin disinfection |
| US8119115B2 (en) | 2006-02-09 | 2012-02-21 | Gojo Industries, Inc. | Antiviral method |
| US20070275929A1 (en) * | 2006-05-24 | 2007-11-29 | The Dial Corporation | Composition and method for controlling the transmission of noroviruses |
| EP2040544A2 (en) * | 2006-05-26 | 2009-04-01 | The Dial Corporation | Method of inhibiting the transmission of viruses |
| WO2007142919A2 (en) * | 2006-05-30 | 2007-12-13 | The Dial Corporation | Compositions having a high antiviral effeicacy |
| US20070281999A1 (en) * | 2006-05-31 | 2007-12-06 | The Dial Corporation | Alcohol-containing antimicrobial compositions having improved efficacy |
| EP2034826A2 (en) | 2006-06-02 | 2009-03-18 | The Dial Corporation | Method of inhibiting the transmission of influenza virus |
| RU2008152442A (en) * | 2006-06-05 | 2010-07-20 | Дзей Дайл Корпорейшн (Us) | METHODS AND PRODUCTS HAVING HIGH ANTIVIRAL AND ANTI-BACTERIAL EFFICIENCY |
| US11229746B2 (en) | 2006-06-22 | 2022-01-25 | Excelsior Medical Corporation | Antiseptic cap |
| JP2010505964A (en) * | 2006-10-10 | 2010-02-25 | リンチ マイケル | How to inactivate viruses |
| CN101662935A (en) * | 2007-05-04 | 2010-03-03 | 宝洁公司 | Antimicrobial compositions, products, and methods of use |
| US20090062391A1 (en) * | 2007-08-27 | 2009-03-05 | Kent Christopher New | Use of a virucidal ointment in the nares for prevention of transmission and contraction of common colds |
| US20090136430A1 (en) * | 2007-11-27 | 2009-05-28 | Dugger Harry A | Antihistamine/Corticosteroid preparations for the treatment of atopic dermatitis |
| GB0800788D0 (en) * | 2008-01-16 | 2008-02-27 | Glaxo Group Ltd | Niovel formulation |
| JP5126745B2 (en) * | 2008-07-22 | 2013-01-23 | 国立大学法人鳥取大学 | Antiviral agent and antiviral sheet |
| US9078992B2 (en) | 2008-10-27 | 2015-07-14 | Pursuit Vascular, Inc. | Medical device for applying antimicrobial to proximal end of catheter |
| US8106111B2 (en) | 2009-05-15 | 2012-01-31 | Eastman Chemical Company | Antimicrobial effect of cycloaliphatic diol antimicrobial agents in coating compositions |
| US9744125B2 (en) * | 2010-01-15 | 2017-08-29 | Nuance Health, Llc | Use of a virucidal preparation on an area of the face for prevention of transmission or contraction of viral illnesses, or to shorten the duration of, or lessen the severity of viral illnesses |
| CN103037934A (en) | 2010-03-15 | 2013-04-10 | 安特提米派尼克有限公司 | Device and method for delivering medicine into the tympanic cavity, with sliding assist |
| CA2841832C (en) | 2011-07-12 | 2019-06-04 | Pursuit Vascular, Inc. | Device for delivery of antimicrobial agent into a trans-dermal catheter |
| US8841640B1 (en) | 2013-03-13 | 2014-09-23 | Inceptus Technologies, Llc | Apparatus for infection control |
| FR3019714B1 (en) * | 2014-04-10 | 2017-07-07 | Salveco | NEW BIOCIDAL PRODUCTS |
| EP3294404A4 (en) | 2015-05-08 | 2018-11-14 | ICU Medical, Inc. | Medical connectors configured to receive emitters of therapeutic agents |
| FR3045382B1 (en) * | 2015-12-17 | 2020-02-07 | Tereos Starch & Sweeteners Belgium | ANTIBACTERIAL COMPOSITION CONTAINING A MONOETHER OR A MONOACETAL OF DEOXYHEXOSE ALKYL |
| WO2018071717A1 (en) | 2016-10-14 | 2018-04-19 | Icu Medical, Inc. | Sanitizing caps for medical connectors |
| JP6951421B2 (en) | 2017-03-28 | 2021-10-20 | ロンザ・ソリューションズ・アー・ゲー | Water-soluble antibacterial composition |
| WO2018204206A2 (en) * | 2017-05-01 | 2018-11-08 | Icu Medical, Inc. | Medical fluid connectors and methods for providing additives in medical fluid lines |
| KR101968028B1 (en) | 2017-12-26 | 2019-04-10 | 롯데첨단소재(주) | Thermoplastic resin composition and article produced therefrom |
| US11534595B2 (en) | 2018-11-07 | 2022-12-27 | Icu Medical, Inc. | Device for delivering an antimicrobial composition into an infusion device |
| US11517732B2 (en) | 2018-11-07 | 2022-12-06 | Icu Medical, Inc. | Syringe with antimicrobial properties |
| US11541220B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Needleless connector with antimicrobial properties |
| US11541221B2 (en) | 2018-11-07 | 2023-01-03 | Icu Medical, Inc. | Tubing set with antimicrobial properties |
| US11400195B2 (en) | 2018-11-07 | 2022-08-02 | Icu Medical, Inc. | Peritoneal dialysis transfer set with antimicrobial properties |
| EP3883638A1 (en) | 2018-11-21 | 2021-09-29 | ICU Medical, Inc. | Antimicrobial device comprising a cap with ring and insert |
| CN111467338B (en) * | 2020-04-07 | 2021-04-23 | 中国科学院深圳先进技术研究院 | Application of pyroglutamic acid in preparation of medicine for preventing and treating novel coronavirus resistant to new coronary pneumonia |
| EP4255552A1 (en) | 2020-12-07 | 2023-10-11 | ICU Medical, Inc. | Peritoneal dialysis caps, systems and methods |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1407997A (en) * | 1972-08-01 | 1975-10-01 | Procter & Gamble | Controlled sudsing detergent compositions |
| US4136045A (en) * | 1976-10-12 | 1979-01-23 | The Procter & Gamble Company | Detergent compositions containing ethoxylated nonionic surfactants and silicone containing suds suppressing agents |
| US4828912A (en) * | 1981-07-20 | 1989-05-09 | Kimberly-Clark Corporation | Virucidal product having virucidal and/or germicidal properties |
| DE3229097A1 (en) * | 1982-08-04 | 1984-02-09 | Schülke & Mayr GmbH, 2000 Hamburg | Microbicidal agents |
| US5006529A (en) * | 1988-05-27 | 1991-04-09 | Lever Brothers Company | Soap compositions of enhanced antimicrobial effectiveness |
| DE4140473C2 (en) * | 1991-12-09 | 1995-12-21 | Schuelke & Mayr Gmbh | Skin antiseptic and hand sanitizer |
| AU671208B2 (en) * | 1993-06-30 | 1996-08-15 | Colgate-Palmolive Company, The | Anti-bacterial cleansing composition |
| US5681802A (en) * | 1994-06-01 | 1997-10-28 | Lever Brothers Company, Division Of Conopco, Inc. | Mild antimicrobial liquid cleansing formulations comprising buffering compound or compounds as potentiator of antimicrobial effectiveness |
| US5653970A (en) * | 1994-12-08 | 1997-08-05 | Lever Brothers Company, Division Of Conopco, Inc. | Personal product compositions comprising heteroatom containing alkyl aldonamide compounds |
| US6110445A (en) * | 1995-06-26 | 2000-08-29 | Colgate-Palmotive Company | Oral composition exhibiting improved uptake and retention of antibacterial compounds on dental tissue surfaces |
| GB2309706B (en) * | 1996-01-31 | 2000-02-09 | Reckitt & Colman Inc | Liquid detergent composition comprising quaternary ammonium surfactant having germicidal properties |
| US6190674B1 (en) * | 1997-06-04 | 2001-02-20 | Procter & Gamble Company | Liquid antimicrobial cleansing compositions |
| US6190675B1 (en) * | 1997-06-04 | 2001-02-20 | Procter & Gamble Company | Mild, rinse-off antimicrobial liquid cleansing compositions which provide improved residual benefit versus gram positive bacteria |
| US6488943B1 (en) * | 1999-04-13 | 2002-12-03 | The Procter & Gamble Company | Antimicrobial wipes which provide improved immediate germ reduction |
| TR200201048T2 (en) * | 1999-10-19 | 2002-08-21 | The Procter & Gamble Company | Compositions for the prevention and treatment of cold and flu-like symptoms |
| AU2001234509A1 (en) * | 2000-01-20 | 2001-07-31 | The Procter And Gamble Company | Antimicrobial compositions |
| DE60124906T2 (en) * | 2000-06-05 | 2007-05-24 | S.C. Johnson & Son, Inc., Racine | BIOZIDE CLEANING AGENTS |
| US20020192407A1 (en) * | 2001-03-01 | 2002-12-19 | The Procter & Gamble Company | Pre-moistened wipe with improved feel and softness |
| FR2822377A1 (en) * | 2001-03-23 | 2002-09-27 | Oreal | USE OF FIBERS AS ANTI-IRRITANT AGENT IN A COSMETIC OR DERMATOLOGICAL COMPOSITION |
| US6846846B2 (en) * | 2001-10-23 | 2005-01-25 | The Trustees Of Columbia University In The City Of New York | Gentle-acting skin disinfectants |
| US7067227B2 (en) | 2002-05-23 | 2006-06-27 | Applied Materials, Inc. | Sensitized chemically amplified photoresist for use in photomask fabrication and semiconductor processing |
| NZ536482A (en) | 2002-06-21 | 2007-03-30 | Procter & Gamble | Antimicrobial compositions, hygiene and personal care products and use thereof |
| US20040001797A1 (en) * | 2002-06-21 | 2004-01-01 | Abel Saud | Antimicrobial compositions, products and methods employing same |
| US20050260243A1 (en) * | 2004-04-26 | 2005-11-24 | The Procter & Gamble Company | Method of treating microbial plant diseases |
-
2005
- 2005-04-25 US US11/113,505 patent/US20050271711A1/en not_active Abandoned
- 2005-04-26 AU AU2005237546A patent/AU2005237546B2/en not_active Ceased
- 2005-04-26 AR ARP050101645A patent/AR052399A1/en unknown
- 2005-04-26 EP EP10012775A patent/EP2298351A3/en not_active Withdrawn
- 2005-04-26 WO PCT/US2005/014279 patent/WO2005105070A2/en active Application Filing
- 2005-04-26 EP EP05741948A patent/EP1740166B1/en not_active Not-in-force
- 2005-04-26 MX MXPA06012442A patent/MXPA06012442A/en active IP Right Grant
- 2005-04-26 ES ES05741948T patent/ES2360803T3/en active Active
- 2005-04-26 CN CNA2005800125491A patent/CN1946428A/en active Pending
- 2005-04-26 JP JP2007509738A patent/JP2007534701A/en active Pending
- 2005-04-26 CA CA002686815A patent/CA2686815A1/en not_active Abandoned
- 2005-04-26 AT AT05741948T patent/ATE492272T1/en not_active IP Right Cessation
- 2005-04-26 BR BRPI0510327-4A patent/BRPI0510327A/en not_active IP Right Cessation
- 2005-04-26 CA CA002562329A patent/CA2562329C/en active Active
- 2005-04-26 DE DE602005025466T patent/DE602005025466D1/en active Active
-
2006
- 2006-10-26 IL IL178894A patent/IL178894A0/en unknown
- 2006-11-27 NO NO20065457A patent/NO20065457L/en not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11026422B2 (en) | 2017-09-26 | 2021-06-08 | Ecolab Usa Inc. | Acid/anionic antimicrobial and virucidal compositions and uses thereof |
| US11937602B2 (en) | 2017-09-26 | 2024-03-26 | Ecolab Usa Inc. | Solid acid/anionic antimicrobial and virucidal compositions and uses thereof |
| US11950595B2 (en) | 2017-09-26 | 2024-04-09 | Ecolab Usa Inc. | Acid/anionic antimicrobial and virucidal compositions and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2005237546A1 (en) | 2005-11-10 |
| EP2298351A2 (en) | 2011-03-23 |
| EP1740166B1 (en) | 2010-12-22 |
| AR052399A1 (en) | 2007-03-21 |
| IL178894A0 (en) | 2007-03-08 |
| MXPA06012442A (en) | 2007-01-17 |
| BRPI0510327A (en) | 2007-10-23 |
| CN1946428A (en) | 2007-04-11 |
| JP2007534701A (en) | 2007-11-29 |
| EP1740166A2 (en) | 2007-01-10 |
| CA2686815A1 (en) | 2005-11-10 |
| US20050271711A1 (en) | 2005-12-08 |
| NO20065457L (en) | 2006-11-27 |
| ATE492272T1 (en) | 2011-01-15 |
| ES2360803T3 (en) | 2011-06-09 |
| WO2005105070A3 (en) | 2006-03-16 |
| CA2562329A1 (en) | 2005-11-10 |
| AU2005237546B2 (en) | 2009-09-10 |
| DE602005025466D1 (en) | 2011-02-03 |
| EP2298351A3 (en) | 2012-06-06 |
| WO2005105070A2 (en) | 2005-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2562329C (en) | Therapeutic antimicrobial compositions and methods | |
| Hübner et al. | Octenidine dihydrochloride, a modern antiseptic for skin, mucous membranes and wounds | |
| CN101137357B (en) | Antimicrobial compositions comprising esters of hydroxycarboxylic acids | |
| CN102908362B (en) | Antiseptic compositions and methods of use | |
| JP5782603B2 (en) | Antibacterial foaming soap | |
| US20110117032A1 (en) | Santising compositions and methods | |
| US6413921B1 (en) | Antimicrobial composition containing parachlorometaxylenol (PCMX) | |
| SK285361B6 (en) | Antimicrobial composition and its use for treatment of herpex simplex virus diseases and other infectious diseases | |
| WO2008031090A1 (en) | Compositions for the treatment of hoof diseases | |
| CN104398500A (en) | Antimicrobial compositions and methods | |
| US20080057136A1 (en) | Disinfecting Composition and Methods of Making and Using Same | |
| US20100120915A1 (en) | Antimicrobials and related methods | |
| CN113631155A (en) | Disinfectant composition, preparation method and application thereof | |
| CN102614113A (en) | Compound washing-free disinfection gel | |
| US9855205B2 (en) | Use of zinc coceth sulfate as an antibacterial agent against propionibacterium acnes | |
| US20230301884A1 (en) | Antiseptic compositions | |
| JP2019509353A (en) | Treatment of skin conditions and diseases associated with microbial biofilms | |
| CN113521042A (en) | Alcohol-free wash-free virus inactivation disinfectant special for children and preparation method thereof | |
| CN104784164A (en) | Protein-based skin cleaning disinfectant and preparation method thereof | |
| AU2020291943A1 (en) | Compositions, kits, methods and uses for preventing microbial growth | |
| CN107737131A (en) | A kind of skin and mucosa damages antibacterial disinfectant and preparation method | |
| US20230126284A1 (en) | Antiseptic compositions | |
| CN100998577A (en) | Triclosan compounding lotion for external use and its preparing method | |
| CN117224573A (en) | Cleaning disinfectant for veterinary cow hooves and preparation method thereof | |
| CN106580939A (en) | Chlorhexidine gluconate disinfectant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |